~Comprehensive Commentary Provides Insights
and Implementation Guidance for US Healthcare Professionals
by NKF and KDOQI~
NEW
YORK, June 21, 2023 /PRNewswire/ -- The National
Kidney Foundation (NKF) and its Kidney Disease Outcomes Quality
Initiative (KDOQI) are pleased to announce the publication of the
KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline
for the Management of Glomerular Diseases. This new comprehensive
review, published today in the American Journal of Kidney Disease
(AJKD), finds generally broad agreement with the KDIGO
guidelines.
The 2021 KDOQI Guideline on the Management
of Glomerular Disease is a tour-de-force compendium for glomerular
diseases.
Glomerular diseases, which impact the kidney's filtering units,
have witnessed significant advancements in molecular research and
the introduction of novel therapeutic approaches over the past
decade. The KDIGO 2021 Clinical Practice Guideline for the
Management of Glomerular Diseases marks a significant update to the
previous set of recommendations published in 2012. The KDOQI
working group crafted a chapter-by-chapter companion article to
provide specific commentary on the implementation of the KDIGO 2021
guidelines within the United
States.
"The 2021 KDIGO Guideline on the Management of Glomerular
Disease is a tour-de-force compendium and reference for the
treatment of glomerular diseases throughout the world," said
Laurence Beck, Jr. MD, PhD,
Associate Professor of Medicine at the Boston
University School of Medicine and co-chair of the KDOQI
Commentary workgroup. "The KDOQI working group has tried to put
this document into context for US nephrologists by explaining some
of the more nuanced points, updating some important clinical trial
information that was not present in the 2021 KDIGO document, and
pointing out areas of controversy in some topic areas. As the
KDIGO guideline is intended to be a living document with regular
updates of the individual chapters, we also hope to provide updates
to our US Commentary as this living document grows and
matures."
In the commentary, esteemed experts in the field, including
Laurence H. Beck Jr., MD, PhD;
Isabelle Ayoub, MD, MPH;
Dawn Caster, MD, FASN; Michael J. Choi, MD; Jason Cobb, MD; Duvuru
Geetha; Michelle N. Rheault,
MD; Shikha Wadhwani, MD, MS;
Timothy Yau, MD; and William L. Whittier, MD, FASN, have contributed
their invaluable insights. Their collective expertise from renowned
institutions across the country ensures a comprehensive and diverse
perspective on glomerular diseases and their management.
This review serves as a vital resource for healthcare
professionals and researchers, offering valuable insights into the
latest advancements and clinical utility of the KDIGO 2021
guidelines in the United States.
By contextualizing the guidelines within the US healthcare
landscape, the KDOQI US Commentary facilitates their effective
implementation and impact on patient care.
The full KDOQI US Commentary on the 2021 KDIGO Clinical Practice
Guideline for the Management of Glomerular Diseases is available
here.
A podcast on the Guideline review can be found here.
To learn more about kidney disease and how to maintain
optimal kidney health visit www.kidney.org/.
About Kidney Disease
In the United States, 37
million adults are estimated to have kidney disease, also known
as chronic kidney disease—and approximately 90 percent don't
know they have it. 1 in 3 American adults are at risk for
chronic kidney disease. Risk factors for kidney disease
include: diabetes, high blood pressure, heart
disease, obesity, and family history. People of African
American, Hispanic, American Indian, Asian, or Pacific Islander
descent are at increased risk for developing the
disease. African Americans are almost 4 times more likely than
White Americans to have kidney failure. Hispanics are 1.3
times more likely than non-Hispanics to have kidney failure.
About National Kidney Foundation
The National Kidney Foundation (NKF) is the largest, most
comprehensive, and longstanding patient-centric organization
dedicated to the awareness, prevention, and treatment of kidney
disease in the U.S. For more information about NKF,
visit www.kidney.org.
About the American Journal of Kidney Diseases
The American Journal of Kidney
Diseases (AJKD), the official journal of the
National Kidney Foundation, is recognized worldwide as a leading
source of information devoted to clinical nephrology practice and
clinical research. Articles selected for publication in AJKD
undergo a rigorous consideration process, supporting the journal's
goal to communicate important new information in clinical
nephrology in a way that strengthens knowledge and helps physicians
to provide their patients with the highest standard of care.
Facebook.com
www.kidney.org
twitter.com/nkf
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-kdoqi-commentary-of-2021-kdigo-clinical-practice-guideline-for-glomerular-diseases-published-301856831.html
SOURCE The National Kidney Foundation